Alembic Pharmaceuticals Limited — Important, 04-04-2025: Statement of utilization of issue proceeds

The company has announced a statement outlining the utilization of proceeds from its recent issuance. A total of ₹100 crore (cr) has been allocated primarily for expanding operations and enhancing product development. This strategic allocation aims to strengthen competitive positioning and operational efficiency. The enhanced capabilities may attract investor interest, reflecting a positive outlook on future growth potential. However, close monitoring of execution will be essential for maintaining momentum and ensuring that the intended benefits materialize effectively.